Note: This story was updated Dec. 15, 2025, to clarify the FDA approval covers a new oral pellet formulation of…
Articles by Marisa Wexler, MS
On-demand treatment with deucrictibant can help resolve swelling attacks in people with all major forms of hereditary angioedema (HAE),…
A European Medicines Agency (EMA) committee recommended that Dawnzera (donidalorsen) be approved to prevent swelling attacks in hereditary…
For most people with hereditary angioedema (HAE) given on-demand treatment in clinical trials with the now-approved therapy Ekterly…
Biocryst Pharmaceuticals has sold the European rights to Orladeyo (berotralstat), its approved oral therapy for preventing swelling attacks…
Ekterly (sebetralstat) is now approved by both the European Commission and Swissmedic as an on-demand treatment to manage swelling…
A monthly injection therapy developed by CSL Behring has won approval from Health Canada to prevent swelling attacks in…
Kaken Pharmaceutical has secured the rights to develop and commercialize navenibart, an investigational treatment for hereditary angioedema…
People with hereditary angioedema (HAE) types 1 and 2 had fewer swelling attacks and reported improvements in quality of…
In the years following treatment with the gene-editing therapy lonvoguran ziclumeran, or lonvo-z — also known as NTLA-2002 —…